[Galectin-3, Markers of Oxidative Stress and Renal Dysfunction in Patients With Chronic Heart Failure]

E A Medvedeva1, I I Berezin1, Y V Shchukin1

  • 1Samara State Medical University, Samara, Russia.

Kardiologiia
|August 2, 2017
PubMed

Insights

In chronic heart failure (CHF) patients with prior myocardial infarction, galectin-3 levels increase with disease severity. Galectin-3 correlates with markers of kidney dysfunction and oxidative stress.

Area of Science:

  • Cardiology
  • Nephrology
  • Biochemistry

Background:

  • Chronic heart failure (CHF) is often associated with renal dysfunction and oxidative stress.
  • Galectin-3 is implicated in cardiac remodeling and fibrosis.
  • Understanding the interplay between galectin-3, renal function, and oxidative stress in CHF is crucial.

Purpose of the Study:

  • To determine plasma galectin-3 levels in patients with chronic heart failure (CHF) of varying severity.
  • To assess markers of renal dysfunction and oxidative stress in these patients.
  • To investigate the correlations between galectin-3, renal dysfunction, and oxidative stress markers in CHF.

Main Methods:

  • 157 CHF patients with prior myocardial infarction were enrolled and categorized by NYHA functional class (II, III, IV).
  • Clinical examination, echocardiography, and laboratory tests were performed.
  • Plasma levels of galectin-3, NT-proBNP, oxidized low-density lipoprotein cholesterol (oxLDLC), SH-groups, creatinine, uric acid, and cystatin-C were measured.

Main Results:

  • Galectin-3 levels significantly increased with CHF severity (median 10, 19, and 38 ng/ml for NYHA class II, III, and IV, respectively; p<0.001).
  • Galectin-3 positively correlated with oxLDLC (r=0.52-0.63, p<0.01) and negatively with SH-groups (r=-0.58 to -0.71, p<0.01).
  • Significant correlations were observed between galectin-3 and cystatin-C, glomerular filtration rate, and uric acid.

Conclusions:

  • Plasma galectin-3 concentration is associated with CHF severity in patients with prior myocardial infarction.
  • Galectin-3 levels correlate significantly with markers of renal dysfunction and plasma oxidative stress.
  • These findings suggest galectin-3 as a potential biomarker reflecting the complex pathophysiology of CHF.
Abstract

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
693
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
633
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
442
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
979